Pancreaticoduodenectomies with Concurrent Colectomies: Indications, Technical Issues, Complications, and Oncological Outcomes.
Traian DumitrascuPublished in: Journal of clinical medicine (2023)
Multi-visceral resections for colon and pancreatic cancer (PDAC) are feasible, safe, and justified for early and late outcomes. However, the use of pancreaticoduodenectomy (PD) with concurrent colectomies is highly debatable in terms of morbidity and oncological benefits. Based on current literature data, this review assesses the early and long-term outcomes of PD with colectomies. The association represents a challenging but feasible option for a few patients with PDAC or locally advanced right colon cancer when negative resection margins are anticipated because long-term survival can be achieved. Concurrent colectomies during PD should be cautiously approached because they may significantly increase complication rates, including severe ones. Thus, patients should be fit enough to overcome potential severe complications. Patients with PD and colectomies can be classified as borderline resectable, considering the high risk of developing postoperative complications. Carefully selecting patients suitable for PD with concurrent colectomies is paramount to mitigate the potentially severe complications of the two surgical procedures and maximize the oncological benefits. These procedures should be performed at high-volume centers with extensive experience in pancreatectomies and colectomies, and each patient situation should be assessed using a multimodal approach, including high-quality imaging and neoadjuvant therapies, in a multidisciplinary team discussion.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- neoadjuvant chemotherapy
- squamous cell carcinoma
- chronic kidney disease
- ejection fraction
- phase ii study
- radiation therapy
- newly diagnosed
- risk factors
- early onset
- prognostic factors
- systematic review
- radical prostatectomy
- prostate cancer
- metabolic syndrome
- machine learning
- high resolution
- risk assessment
- mass spectrometry
- quality improvement
- photodynamic therapy
- drug induced
- pain management
- open label
- liver metastases
- fluorescence imaging
- patient reported